Kura Oncology to Participate in Three Upcoming Investor Conferences

Rhea-AI Summary

Kura Oncology (Nasdaq: KURA) will participate in three investor conferences in March 2026: TD Cowen Health Care Conference on March 4 at 11:50 a.m. ET, Leerink Partners Global Biopharma Conference on March 10 at 10:40 a.m. ET, and Barclays Global Healthcare Conference on March 12 at 9:00 a.m. ET.

Live audio webcasts will be available in the Investors section of Kura’s website, with archived replays posted after each event.

News Market Reaction – KURA

+2.15%

+2.15% Session close to close

In the Feb 25 session, KURA gained 2.15%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the following investor conferences:

TD Cowen Health Care Conference
March 4, 2026
11:50 a.m. ET / 8:50 a.m. PT

Leerink Partners Global Biopharma Conference
March 10, 2026
10:40 a.m. ET / 7:40 a.m. PT

Barclays Global Healthcare Conference
March 12, 2026
9:00 a.m. ET / 6:00 a.m. PT

Live audio webcasts will be available in the Investors section of Kura’s website at https://kuraoncology.com/, with archived replays available following all three events.

About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™, the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.

Kura Contact

Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com

FAQ

When will KURA present at the TD Cowen Health Care Conference in 2026?

KURA will present on March 4, 2026 at 11:50 a.m. ET. According to Kura Oncology, a live audio webcast will be available in the Investors section of the company website and archived for later replay.

How can investors listen to KURA’s Leerink Partners Global Biopharma Conference presentation on March 10, 2026?

Investors can listen via a live audio webcast on Kura’s investor website. According to Kura Oncology, the live audio webcast for the March 10, 2026 presentation will also be archived after the event for on-demand playback.

What time is KURA scheduled to speak at the Barclays Global Healthcare Conference on March 12, 2026?

KURA is scheduled for March 12, 2026 at 9:00 a.m. ET. According to Kura Oncology, the presentation will be webcast live on the company’s Investors page and an archived replay will be posted following the event.

Will KURA provide archived replays of its March 2026 investor conference presentations?

Yes, KURA will provide archived replays after each event. According to Kura Oncology, live audio webcasts will be available during the sessions and archived recordings will be posted in the Investors section of the company website.

Which investor conferences will KURA attend in March 2026 and where can I find the webcasts?

KURA will attend TD Cowen (March 4), Leerink Partners (March 10), and Barclays Global Healthcare (March 12), 2026. According to Kura Oncology, live audio webcasts and archived replays will be available in the Investors section of the company website.